Navigation Links
Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
Date:1/13/2009

tibody, is being tested in a phase 1 clinical trial for the treatment of patients with gastrointestinal or lung cancer. In addition, Micromet is conducting a phase 1 clinical trial with adecatumumab, a human monoclonal antibody binding to EpCAM, investigating its use in combination with docetaxel for patients with metastatic breast cancer. A phase 2 study of adecatumumab in colorectal cancer patients with liver metastases is planned to be initiated this year.

(1) Dorothea Maetzel, Sabine Denzel, Brigitte Mack, Martin Canis, Philip Went, Michael Benk, Cuong Kieu, Peer Papior, Patrick A. Baeuerle, Markus Munz & Olivier Gires. Nuclear signalling by tumor-associated antigen EpCAM. Nature Cell Biology. Published online: 11 January 2009; | doi:10.1038/ncb1824

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, Maryland and Munich, Germany. The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company uses its proprietary BiTE(R) antibody platform to create a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease-related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell a
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
2. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
3. Wound Management Technologies, Inc. Announces a Published Case Study
4. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
5. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
8. The Protein Tomography(TM) Award Now Published on Sidecs Homepage
9. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
10. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
11. AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH to be Published in European Urology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Mass. , Feb. 27, 2015 ... of the NCATS rare-diseases portfolio " in ... a new financing technique to reduce the risk ... diseases and potentially unlock new levels of funding ... The product of a unique collaboration between scientists ...
(Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... differences among countries. This is what medical researchers ... from biobanks in their research. For one thing, ... international studies. In the latest issue of Nature ... (CBE), together with leading biobank researchers, put forward a ...
... of disease is often critical to how successful treatment can ... is a hot research field, where every small step is ... issue of Molecular & Cellular Proteomics, Uppsala University researchers describe ... Proteins build up the bodys cells and tissues, and our ...
... Washington DC*-- Key components of a new approach to ... Friday as part of a twelve-day, low-Earth orbit experiment ... prelude future journeys to Mars. , The new approach ... pregnancy test kits. The so-called immunoassays are embodied in ...
Cached Biology Technology:Long-awaited international ethical guidelines for biobank researchers 2Life on Mars 'pregnancy test' successfully launched 2
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... by researchers at Hasbro Childrens Hospital, the pediatric division ... York, offers new insight into the role that the ... disease. The cystic fibrosis transmembrane conductance regulator (CFTR) ... Mutations of this protein are associated with cystic fibrosis ...
... which tend to involve localized changes in sea surface ... than the more uniform patterns of global warming, a ... debate over the effect of global warming on hurricanes, ... more favorable environment for hurricane development and intensification. However, ...
... Viejo, California) Ossur, an emerging leader in the ... of integration, is pleased to announce that the Journal ... two year cervical collar study performed by the Mayo ... Interface Pressure from Four Cervical Collars, finds that Ossurs ...
Cached Biology News:Study uncovers clues to cystic fibrosis gene dysfunction and gastrointestinal disease 2Climate's remote control on hurricanes 2Mayo Clinic study: Ossur's collars superior in immobilization and reduction of pressure 2